OpenWetWare:Getting started: Difference between revisions

From OpenWetWare
Jump to navigationJump to search
No edit summary
No edit summary
(140 intermediate revisions by 94 users not shown)
Line 1: Line 1:
{{Template:Webster}}
{{OpenWetWare:Getting started/Introduction}} <!-- PLEASE DO NOT MAKE EDITS TO THIS PAGE! If you would like to make test edits, please refer here: http://openwetware.org/wiki/Sandbox -->


{|cellspacing="5" cellpadding="10" style="background:#000099; width: 750px;"
== Introduction ==
|-valign="top"
A hematopoietic stem cell is a stem cell that is derived from the bone marrow marrow or the blood of a subject. These stem cells are pluripotent and thus have the ability to be transformed into any other type of blood cell or immune cell. Their role within the blood is to keep the body constantly replenished with blood as the blood cells must be replaced every day. There are two different types of hematopoietic stem cells, long term and short term. However it is extremely difficult for researchers to differentiate between the two different types of stem cells once they are removed from the blood or bone marrow. The difference between the two types of cells are that long term can regenerate indefinitely while short term stem cells cannot renew themselves over a long period of time(Toshihisa 2013).
|style="background:#ffffff"|
<h3><font color=#2F9258>Lab members</font></h3>
<br>
[[Image:Webster.jpg]]


|style="background:#ffffff"|
[[Image:Stem cell.jpg]]


<h3><font color=#2F9258>Recent publications</font></h3>
== Motivation ==
Hematopoietic stem cell have the potential to be used to influence the immune system in a myriad of ways as well as to influence the production of red blood cells in the body. By better understanding these cells and being able to manipulate these cells, cures for autoimmune diseases and cancers can be possibly found. Furthermore artificial blood can be produced so that those who need blood transfusions may be able to more readily get them.


== Current Work ==
Hematopoietic stem cells can be taken from a donor patient and inserted into a patient with a compromised immune system or bone marrow. This process is called hematopoietic stem cell transplantation, and the donor stem cells are inserted via an IV into the patient. This transplantation method can be used to treat patients who have diseases such as neuroblastoma or Non-Hodgkin Lymphoma. However there are numerous potential side effects including infection as well as Graft-versus-host disease(Regenerative 2006).
Another use for hematopoietic stem cells are to use them to induce tolerance in solid organ grafts. By introducing these stem cells into the organ that’s been transplanted, the autoimmune response to that new organ is reduced or eliminated. This effect was examined in newborn mice, where transplanted organs were accepted by the host mice’s body for the remainder of its life and no autoimmune response to the new organ observed (Hematopoietic 2011). The reason for the acceptance of the donated organ is due to a lower negative T cell response, essentially meaning that T cells won’t recognize the new organ as an invader and attack it(Regenerative 2006).


<h3><font color=#2F9258>*'''Biomaterials'''</font></h3>
[[Image:Boom.png]]


== Future Work/Complications ==
Research has been done on whether or not hematopoietic stem cells can be used to heal other parts of the body rather than blood or bone marrow. There is evidence to suggest that hematopoietic stem cells tend to gravitate towards injured areas of the body and heal damaged tissues there(Hematopoietic 2011). There is also the potential of these stem cells being turned other types of cells such as bone cells or brain cells as they are pluripotent cell. However the viability of this method is still in question as the research into this is still fairly young and as yet unexplored although the potential is still there.
One of the key obstacles to further work in this area is the limited supply of hematopoietic stem cells as well as the very large numbers needed by patients for each treatment. This is due to the host’s body tendency to attack the donated cells. Another obstacle of these stem cells is the inability of scientists to be able to differentiate between long term and short term hematopoietic stem cells, as only the long term stem cells are useful for growing cultures. These long term cells are also fairly rare, only occurring 1:10,000 normal red blood cells(Hematopoietic 2011).


1. The effect of nanotopography on calcium and phosphorus deposition on metallic materials in vitro 
== References ==
Biomaterials, Volume 27, Issue 16, June 2006, Pages 3064-3074
  ==Toshihisa Tsuruta (2013). Recent Advances in Hematopoietic Stem Cell Gene Therapy, Innovations in Stem Cell Transplantation, Prof. Taner Demirer (Ed.), ISBN: 978-953-51-0980-8, InTech, DOI: 10.5772/53587. Available from: http://www.intechopen.com/books/innovations-in-stem-cell-transplantation/recent-advances-in-hematopoietic-stem-cell-gene-therapy
'''Brian C. Ward and Thomas Jay Webster'''
  ==Regenerative Medicine. Department of Health and Human Services. Chapter 2: Bone Marrow (Hematopoietic) Stem Cells. August 2006. http://stemcells.nih.gov/info/scireport/2006report.htm
   
  ==Hematopoietic Stem Cells . In Stem Cell Information [World Wide Web site]. Bethesda, MD: National Institutes of Health, U.S. Department of Health and Human Services, 2011 [cited Wednesday, January 28, 2015] Available at <http://stemcells.nih.gov/info/scireport/pages/chapter5.aspx>
2. Using hydroxyapatite nanoparticles and decreased crystallinity to promote osteoblast adhesion similar to functionalizing with RGD  
Biomaterials, Volume 27, Issue 14, May 2006, Pages 2798-2805
'''Ganesan Balasundaram, Michiko Sato and Thomas J. Webster'''
3. Increased osteoblast functions on undoped and yttrium-doped nanocrystalline hydroxyapatite coatings on titanium
Biomaterials, Volume 27, Issue 11, April 2006, Pages 2358-2369
'''Michiko Sato, Marisa A. Sambito, Arash Aslani, Nader M. Kalkhoran, Elliott B. Slamovich and Thomas Jay Webster'''
4. Helical rosette nanotubes: A biomimetic coating for orthopedics? 
Biomaterials, Volume 26, Issue 35, December 2005, Pages 7304-7309
'''Ai Lin Chun, Jesus G. Moralez, Thomas J. Webster and Hicham Fenniri'''
 
5. Analytically derived material properties of multilaminated extracellular matrix devices using the ball-burst test
Biomaterials, Volume 26, Issue 27, September 2005, Pages 5518-5531
'''Donald O. Freytes, Ann E. Rundell, Jonathan Vande Geest, David A. Vorp, Thomas J. Webster and Stephen F. Badylak'''
6. Accelerated chondrocyte functions on NaOH-treated PLGA scaffolds
Biomaterials, Volume 26, Issue 16, June 2005, Pages 3075-3082
Grace E. Park, Megan A. Pattison, Kinam Park and Thomas J. Webster
 
7. Three-dimensional, nano-structured PLGA scaffolds for bladder tissue replacement applications 
Biomaterials, Volume 26, Issue 15, May 2005, Pages 2491-2500
Megan A. Pattison, Susan Wurster, Thomas J. Webster and Karen M. Haberstroh
8. Enhanced osteoblast adhesion on hydrothermally treated hydroxyapatite/titania/poly(lactide-co-glycolide) sol–gel titanium coatings
Biomaterials, Volume 26, Issue 12, April 2005, Pages 1349-1357
Michiko Sato, Elliott B. Slamovich and Thomas J. Webster
 
9. Increased osteoblast functions on theta+delta nanofiber alumina 
Biomaterials, Volume 26, Issue 9, March 2005, Pages 953-960
Thomas J. Webster, Elaine L. Hellenmeyer and Rachel L. Price
10. Increased viable osteoblast density in the presence of nanophase compared to conventional alumina and titania particles 
Biomaterials, Volume 25, Issue 18, August 2004, Pages 4175-4183
Luke G. Gutwein and Thomas J. Webster
SummaryPlus | Full Text + Links | PDF (383 K) 
 
11. Increased osteoblast adhesion on nanophase metals: Ti, Ti6Al4V, and CoCrMo Biomaterials, Volume 25, Issue 19, August 2004, Pages 4731-4739
Thomas J. Webster and Jeremiah U. Ejiofor
 
12. Decreased fibroblast cell density on chemically degraded poly-lactic-co-glycolic acid, polyurethane, and polycaprolactone  • ARTICLE
Biomaterials, Volume 25, Issue 11, May 2004, Pages 2095-2103
Rylie J. Vance, Derick C. Miller, Anil Thapa, Karen M. Haberstroh and Thomas J. Webster
SummaryPlus | Full Text + Links | PDF (432 K) 
 
13. Osteoblast response to hydroxyapatite doped with divalent and trivalent cations 
Biomaterials, Volume 25, Issue 11, May 2004, Pages 2111-2121
Thomas J. Webster, Elizabeth A. Massa-Schlueter, Jennifer L. Smith and Elliot B. Slamovich
 
14.   
Biaxial strength of multilaminated extracellular matrix scaffolds  • ARTICLE
Biomaterials, Volume 25, Issue 12, May 2004, Pages 2353-2361
Donald O. Freytes, Stephen F. Badylak, Thomas J. Webster, Leslie A. Geddes and Ann E. Rundell
SummaryPlus | Full Text + Links | PDF (537 K) 
15.   
Altered responses of chondrocytes to nanophase PLGA/nanophase titania composites  • ARTICLE
Biomaterials, Volume 25, Issues 7-8, March-April 2004, Pages 1205-1213
Jennifer K. Savaiano and Thomas J. Webster
SummaryPlus | Full Text + Links | PDF (242 K)  
16.  
Decreased functions of astrocytes on carbon nanofiber materials  • ARTICLE
Biomaterials, Volume 25, Issues 7-8, March-April 2004, Pages 1309-1317
Janice L. McKenzie, Michael C. Waid, Riyi Shi and Thomas J. Webster
SummaryPlus | Full Text + Links | PDF (406 K) 
17.   
Endothelial and vascular smooth muscle cell function on poly(lactic-co-glycolic acid) with nano-structured surface features  • ARTICLE
Biomaterials, Volume 25, Issue 1, January 2004, Pages 53-61
Derick C. Miller, Anil Thapa, Karen M. Haberstroh and Thomas J. Webster
SummaryPlus | Full Text + Links | PDF (573 K)
18.  
Nano-structured polymers enhance bladder smooth muscle cell function  • ARTICLE
Biomaterials, Volume 24, Issue 17, August 2003, Pages 2915-2926
Anil Thapa, Derick C. Miller, Thomas J. Webster and Karen M. Haberstroh
SummaryPlus | Full Text + Links | PDF (553 K) 
19.  
  Selective bone cell adhesion on formulations containing carbon nanofibers  • ARTICLE
Biomaterials, Volume 24, Issue 11, May 2003, Pages 1877-1887
Rachel L. Price, Michael C. Waid, Karen M. Haberstroh and Thomas J. Webster
SummaryPlus | Full Text + Links | PDF (3523 K) 
20.   
Enhanced functions of osteoblasts on nanometer diameter carbon fibers  • ARTICLE
Biomaterials, Volume 23, Issue 15, August 2002, Pages 3279-3287
Kathy L. Elias, Rachel L. Price and Thomas J. Webster
SummaryPlus | Full Text + Links | PDF (507 K) 
21.   
Enhanced osteoclast-like cell functions on nanophase ceramics  • ARTICLE
Biomaterials, Volume 22, Issue 11, 1 June 2001, Pages 1327-1333
Thomas J. Webster, Celaletdin Ergun, Robert H. Doremus, Richard W. Siegel and Rena Bizios
SummaryPlus | Full Text + Links | PDF (428 K) 
22.  
Enhanced functions of osteoblasts on nanophase ceramics  • ARTICLE
Biomaterials, Volume 21, Issue 17, September 2000, Pages 1803-1810
Thomas J. Webster, Celaletdin Ergun, Robert H. Doremus, Richard W. Siegel and Rena Bizios
SummaryPlus | Full Text + Links | PDF (279 K) 
23.   
Osteoblast adhesion on nanophase ceramics  • ARTICLE
Biomaterials, Volume 20, Issue 13, July 1999, Pages 1221-1227
Thomas J. Webster, Richard W. Siegel and Rena Bizios
Abstract | PDF (336 K) 
 
<br>
 
 
 
|}<br style="clear:both" />
<div style="padding: 10px; width: 720px; border: 5px solid #000099;">
 
<h3><font color=#2F9258>Research</font></h3>
Webster Lab is majoring nano-tissue engineering
</div><br>
 
<div style="padding: 10px; width: 720px; border: 5px solid #000099;">
 
==<font color=#2F9258>Recent announcements</font>==
*'''10/04/06''' - We have a lab meeting (presenter: Lijie Zheng)!
*'''09/28/06''' - Set Up a New Home Page!
 
__NOTOC__
 
</div><br>
 
Thanks to [[BE Board]] for this template

Revision as of 09:28, 29 January 2015

What is OpenWetWare?

OpenWetWare is an effort to promote the sharing of information, know-how, and wisdom among researchers and groups who are working in biology & biological engineering. Lots of people are constantly improving OpenWetWare, making frequent changes, all of which are recorded on article histories and recent changes.

The first step, if you haven't done so already, is to set up a user account so you can edit pages.

How can I help?

Click edit to change an article

Don't be afraid to editanyone can edit almost any page, and we encourage you to be bold (but please don't vandalize)! Find something that can be improved, either in content, grammar or formatting, and fix it.

You can't break OpenWetWare. Anything can be fixed or improved later. So go ahead, edit an article and help make OpenWetWare the best information source on the Internet!

Make your first edit right now:

  1. Click above
  2. Type a message
  3. Click to save your writing

...or to test your changes



Test edits...

Introduction

A hematopoietic stem cell is a stem cell that is derived from the bone marrow marrow or the blood of a subject. These stem cells are pluripotent and thus have the ability to be transformed into any other type of blood cell or immune cell. Their role within the blood is to keep the body constantly replenished with blood as the blood cells must be replaced every day. There are two different types of hematopoietic stem cells, long term and short term. However it is extremely difficult for researchers to differentiate between the two different types of stem cells once they are removed from the blood or bone marrow. The difference between the two types of cells are that long term can regenerate indefinitely while short term stem cells cannot renew themselves over a long period of time(Toshihisa 2013).

Motivation

Hematopoietic stem cell have the potential to be used to influence the immune system in a myriad of ways as well as to influence the production of red blood cells in the body. By better understanding these cells and being able to manipulate these cells, cures for autoimmune diseases and cancers can be possibly found. Furthermore artificial blood can be produced so that those who need blood transfusions may be able to more readily get them.

Current Work

Hematopoietic stem cells can be taken from a donor patient and inserted into a patient with a compromised immune system or bone marrow. This process is called hematopoietic stem cell transplantation, and the donor stem cells are inserted via an IV into the patient. This transplantation method can be used to treat patients who have diseases such as neuroblastoma or Non-Hodgkin Lymphoma. However there are numerous potential side effects including infection as well as Graft-versus-host disease(Regenerative 2006). Another use for hematopoietic stem cells are to use them to induce tolerance in solid organ grafts. By introducing these stem cells into the organ that’s been transplanted, the autoimmune response to that new organ is reduced or eliminated. This effect was examined in newborn mice, where transplanted organs were accepted by the host mice’s body for the remainder of its life and no autoimmune response to the new organ observed (Hematopoietic 2011). The reason for the acceptance of the donated organ is due to a lower negative T cell response, essentially meaning that T cells won’t recognize the new organ as an invader and attack it(Regenerative 2006).

Future Work/Complications

Research has been done on whether or not hematopoietic stem cells can be used to heal other parts of the body rather than blood or bone marrow. There is evidence to suggest that hematopoietic stem cells tend to gravitate towards injured areas of the body and heal damaged tissues there(Hematopoietic 2011). There is also the potential of these stem cells being turned other types of cells such as bone cells or brain cells as they are pluripotent cell. However the viability of this method is still in question as the research into this is still fairly young and as yet unexplored although the potential is still there. One of the key obstacles to further work in this area is the limited supply of hematopoietic stem cells as well as the very large numbers needed by patients for each treatment. This is due to the host’s body tendency to attack the donated cells. Another obstacle of these stem cells is the inability of scientists to be able to differentiate between long term and short term hematopoietic stem cells, as only the long term stem cells are useful for growing cultures. These long term cells are also fairly rare, only occurring 1:10,000 normal red blood cells(Hematopoietic 2011).

References

==Toshihisa Tsuruta (2013). Recent Advances in Hematopoietic Stem Cell Gene Therapy, Innovations in Stem Cell Transplantation, Prof. Taner Demirer (Ed.), ISBN: 978-953-51-0980-8, InTech, DOI: 10.5772/53587. Available from: http://www.intechopen.com/books/innovations-in-stem-cell-transplantation/recent-advances-in-hematopoietic-stem-cell-gene-therapy
==Regenerative Medicine. Department of Health and Human Services. Chapter 2: Bone Marrow (Hematopoietic) Stem Cells. August 2006. http://stemcells.nih.gov/info/scireport/2006report.htm
==Hematopoietic Stem Cells . In Stem Cell Information [World Wide Web site]. Bethesda, MD: National Institutes of Health, U.S. Department of Health and Human Services, 2011 [cited Wednesday, January 28, 2015] Available at <http://stemcells.nih.gov/info/scireport/pages/chapter5.aspx>